Clinical Trials Browser

OTHER × Interventional × pertuzumab × Clear all

NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Phase 1/2 Active not recruiting

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

HER2-positive Breast Cancer

NCT07459673 2026-05-22

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Phase 2 Recruiting

Breast Neoplasms

NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Phase 2 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT02693535 2026-05-15

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05730712 2026-05-15

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

7 enrolled 10 charts

Prostatic Neoplasms

NCT07053085 2026-05-14

A Study of Surgery and Radiotherapy in People With Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07581795 2026-05-12

SPECTACLE

Phase 2 Not yet recruiting

Advanced HER2-positive Breast Cancer

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT06876714 2026-05-08

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Phase 3 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07220135 2026-05-06

NeoTHERa

Phase 2 Recruiting

Breast Neoplasms

NCT07565324 2026-05-04

UC HER

Phase 2 Not yet recruiting

Breast Neoplasms

NCT03803553 2026-05-01

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT04733118 2026-04-29

PHERGAIN-2

Phase 2 Active not recruiting

Breast Neoplasms

NCT07095023 2026-04-29

OPTIMAL-BC

Phase NA Recruiting

Breast Neoplasms

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Phase 2 Active not recruiting

19 enrolled 26 charts

HER2-positive Metastatic Breast Cancer

NCT07402473 2026-04-23

EUREKA

Phase 2 Recruiting

HER2-positive Early-stage Breast Cancer

NCT03820141 2026-04-20

DTP

Phase 2 Active not recruiting

51 enrolled 12 charts

Breast Neoplasms

NCT02326974 2026-04-17

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Phase 2 Active not recruiting

164 enrolled 19 charts

Breast Neoplasms

NCT07527806 2026-04-17

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07528898 2026-04-14

Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

Phase 2 Not yet recruiting

Breast Neoplasms

NCT02390427 2026-04-09

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT07371585 2026-03-27

TOP-REAL

Phase 2 Recruiting

Breast Neoplasms

NCT07335081 2026-03-24

ctDNA in HER2+ EBC Neoadjuvant Treatment

Phase 2 Recruiting

Breast Neoplasms

NCT05323955 2026-03-17

BRIDGET

Phase 2 Active not recruiting

Brain Neoplasms

NCT04253561 2026-03-16

IPATHER

Phase 1 Completed

Breast Neoplasms

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Phase 2 Recruiting

Breast Neoplasms

NCT07421141 2026-02-27

Opti-HER2

Phase 2 Active not recruiting

Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Phase 2 Recruiting

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

Phase 2 Active not recruiting

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Phase 2 Active not recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Phase 2 Completed

23 enrolled 10 charts

Breast Neoplasms

NCT07340398 2026-01-21

TAYLOR

Phase 2 Recruiting

HER2-positive Early Breast Cancer

NCT05256745 2025-12-24

RAGE

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04193059 2025-11-26

PANSY

Phase 3 Active not recruiting

Breast Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT04425018 2025-11-18

MARGOT

Phase 2 Active not recruiting

174 enrolled 19 charts

Breast Neoplasms

NCT05041842 2025-11-17

InTTercePT

Phase 2 Active not recruiting

Metastatic Breast Cancer With a Isolated Brain Progression

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Phase 2 Active not recruiting

18 enrolled 8 charts

Breast Neoplasms

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT03264547 2025-09-29

EMERALD

Phase 3 Completed

Breast Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Phase 3 Recruiting

Breast Neoplasms